Coeptis Therapeutics, Inc.
COEP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $83 | $29 | $29 | $11 |
| - Cash | $5 | $2 | $4 | $1 |
| + Debt | $0 | $1 | $2 | $1 |
| Enterprise Value | $78 | $28 | $27 | $11 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 18.3% | 219.2% | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 81% | 77.5% | 28.2% | – |
| EBITDA | -$3 | -$4 | -$3 | -$3 |
| % Margin | -1,065.7% | -1,973.9% | -4,841.7% | – |
| Net Income | -$0 | -$4 | -$3 | -$3 |
| % Margin | -67.1% | -1,761.3% | -4,863.3% | – |
| EPS Diluted | -0.58 | -0.95 | -0.99 | 4.09 |
| % Growth | 38.9% | 4% | -124.2% | – |
| Operating Cash Flow | -$2 | -$2 | -$2 | -$1 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$2 | -$2 | -$1 |